Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran,
Virology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran,
Clinical Tuberculosis and Epidemiology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran,
Clinical Pharmacy Department, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran,
Chronic Respiratory Diseases Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Background: Hypersensitivity reaction (HSR) is a major adverse effect of
abacavir (ABC), which occurs in 5-8% of Caucasians. The relationship between
Human Leukocyte Antigen (HLA) and ABC HSR has been reported in various
populations. It has been proposed to administer ABC only to HLA-B*5701
negative patients to avoid this reaction.
The purpose of this study was to assess the prevalence of HLA-B*5701 in
Iranian HIV positive patients. We also sought to find the relationship between
this allele with ABC HSR in patients who received the medication.
Materials and Methods: We screened patients for HLA-B*5701 allele using
SybrGreen real time PCR-melting method on blood samples from HIV positive
patients who were referred to our hospital. The quality of the extracted genome
was evaluated by B-globin housekeeping gene as internal control prior to HLAB*5701 allele screening.
Results: Of 198 HIV-infected patients, 6 (3.0%) had the HLA-B*5701 allele (95%
CI, 1%–5%). Among the 28 patients who were given ABC, one individual had
the HLA-B*5701 allele and experienced ABC HSR.
Conclusion: Prevalence of HLA-B*5701 in Iranian patients was lower than that
in Caucasians but was comparable with that of other Middle Eastern
populations. Screening for HLA-B*5701 before ABC administration as part of
antiretroviral therapy may reduce the risk of HSR.